Show simple item record

 
dc.contributorConsorci Sanitari de Terrassa
dc.contributor.authorBlasi Ibanez, Annabel
dc.contributor.authorMachlab, Salvador
dc.contributor.authorRisco Martínez, Raquel
dc.contributor.authorda Costa-Seixas, João Pedro
dc.contributor.authorHernández, Geovanny
dc.contributor.authorHorta Sangenis, Diana
dc.contributor.authorProfitós Font, Joaquim
dc.date.accessioned2023-05-10T09:42:13Z
dc.date.available2023-05-10T09:42:13Z
dc.date.issued2021-09-16
dc.identifier.citationBlasi A, Machlab S, Risco R, Costa-Seixas JP, Hernández-Cely G, Horta D, et al. A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation. JHEP Rep. 2021 Sep 16;3(6):100363.
dc.identifier.urihttps://hdl.handle.net/11351/9496
dc.descriptionCirrhosis; Endoscopic band ligation; Esophageal varices; Platelet transfusion
dc.description.abstractBackground & aims: Prophylactic administration of platelets and fresh frozen plasma (FFP) has been recommended in patients with cirrhosis with low platelets and/or prolonged international normalized ratio (INR) without scientific evidence to support this practice. In this analysis, we evaluated the use of prophylactic administration of blood products in outpatients with cirrhosis undergoing endoscopic band ligation (EBL). Methods: This is a multicenter retrospective analysis of consecutive EBL procedures in patients with cirrhosis at 4 hospitals in Spain from 01/2010-01/2017. FFP and/or platelet transfusion were given at the discretion of the physician if INR was >1.5 and/or platelet count <50x109/L. Patient demographics, endoscopic findings, bleeding events after EBL, and the use of prophylactic FFP or platelets were recorded. Results: A total of 536 patients underwent 1,472 EBL procedures: 72% male; main etiology HCV and alcohol (72%); median MELD score 11; Child-Pugh A/B/C (59/33/8%). EBL procedures were performed for primary (51%) or secondary (49%) prophylaxis. A median of 2 procedures per patient were performed.1-4 FFP and/or platelets were administered in 41 patients (7.6%). The prophylactic transfusion protocol was followed in 16% and 28% of procedures with high INR and/or low platelets, respectively. Post-EBL bleeding occurred in 26 out of 536 patients (4.8%) and in 33 out of 1,472 procedures (2.2%). Bleeding was due to post-EBL ulcers in 21 patients and due to band dislodgment in 5. In 6 patients, bleeding occurred within 24 hours and in the remaining patients it occurred within 2 weeks after EBL. In those that bled, 7 met criteria for transfusion (2 for FFP and 5 for platelets), of whom only 1 received FFP and 4 received platelets; the remaining 19 patients did not meet criteria for transfusion. There was no association between INR or platelet count and bleeding events. Univariate and multivariate analysis revealed that Child-Pugh and MELD scores were risk factors for post-EBL bleeding. Conclusions: The incidence of post-EBL bleeding is low and is associated with advanced liver disease. Post-EBL bleeding was not related to baseline INR/platelet count and most outpatients with post-EBL bleeding did not meet criteria for prophylactic transfusion. Lay summary: Patients with chronic liver disease or cirrhosis and enlarged veins (varices) of the esophagus that can potentially bleed commonly need an endoscopy to treat these varices with elastic rubber bands (endoscopic band ligation). Some patients have low platelet counts or prolonged coagulation tests. This analysis of 4 centers evaluated the use of prophylactic administration of blood products in outpatients with cirrhosis undergoing endoscopic band ligation. The results showed that bleeding after band ligation is uncommon and that if bleeding occurs it does not seem to be related with coagulation tests or the administration of blood products to prevent bleeding after band ligation of esophageal varices.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesJHEP Reports;3(6)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCirrosi hepàtica
dc.subjectSang - Transfusió
dc.subjectVarices esofàgiques
dc.subject.meshLiver Cirrhosis
dc.subject.meshEsophageal and Gastric Varices
dc.subject.meshBlood Transfusion
dc.titleA multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.jhepr.2021.100363
dc.subject.decscirrosis hepática
dc.subject.decsvarices esofágicas y gástricas
dc.subject.decstransfusión sanguínea
dc.relation.publishversionhttps://doi.org/10.1016/j.jhepr.2021.100363
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.event.productorBiblioteca
dc.contributor.authoraffiliation[Blasi A] Servei d’Anestèsia, Hospital Clínic de Barcelona, Barcelona, Spain. Ciber de Malalties Hepàtiques i Digestives (CIBEREHD), Madrid, Spain. Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Barcelona, Spain. [Machlab S, Costa-Seixas JP] Servei de Malalties Digestives, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain. Institut d'Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Risco R] Servei d’Anestèsia, Hospital Clínic de Barcelona, Barcelona, Spain. [Hernández-Cely G] Servei de Gastroenterologia i Hepatologia, Fundació Cardioinfantil, Colombia. Unitat 6GI, Institut de Malalties Digestives i Metabòliques, Hospital Clínic de Barcelona, Barcelona, Spain. [Horta D] Servei de Gastroenterologia, Hospital Universitari Mutua de Terrassa, Terrassa, Spain. [Profitos J] Servei de Gastroenterologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain
dc.identifier.pmid34765959
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record